Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease

E. Tarasco, AS. von Krogh, R. Hrdlickova, TR. Braschler, T. Iwaniec, PN. Knöbl, E. Hamada, O. Pikovsky, S. Farese, O. Gutwein, P. Kessler, NH. Schultz, C. von Auer, J. Windyga, K. Friedman, I. Hrachovinova, JN. George, M. Matsumoto, R....

. 2022 ; 6 (7) : e12814. [pub] 20221021

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031477

INTRODUCTION: Severe COVID-19 is associated with an important increase of von Willebrand factor and mild lowering of ADAMTS13 activity that may, in the presence of a strong inflammatory reaction, increase the risk of acute thrombotic thrombocytopenic purpura (TTP). Although acute episodes of immune-mediated TTP associated with COVID-19 or SARS-CoV-2 vaccination have been reported, data about clinical evolution of hereditary TTP (hTTP) during the pandemic are scarce. METHOD: We conducted a survey among adult patients of the International Hereditary TTP Registry about SARS-CoV-2 vaccination, COVID-19, and occurrence of acute hTTP episodes. RESULTS: Of 122 adult hTTP patients invited to participate, 86 (70.5%) responded. Sixty-five had been vaccinated (75.6%), of which 14 had received in addition a booster, resulting in 139 individual vaccine shots. Although vaccinations in patients on plasma prophylaxis were done within 1 week of the last plasma infusion, all 23 patients treated with plasma on demand were vaccinated without prior plasma infusions. One patient on uninterrupted weekly plasma infusions presented within 3 days from his second vaccination with neurological symptoms and computed tomography scan 9 days later showed subacute ischemic/hemorrhagic frontal lobe infarction. A second male patient developed acute myocarditis after his second dose of mRNA-1273 vaccine. Twelve (14%) patients had COVID-19, associated with an acute hTTP episode in three of them: one patient had a transient ischemic attack, one a stroke, and a pregnant woman was hospitalized to intensify plasma treatment. DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2.

Blood Center University Hospital Ostrava Ostrava Czech Republic

Center for Clinical Hematology Luzerne Kantonsspital Lucerne Switzerland

Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany

Department for BioMedical Research University of Bern Bern Switzerland

Department of Biostatistics and Epidemiology College of Public Health University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA

Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan

Department of Clinical and Molecular Medicine Faculty of Medicine and Health Sciences Norwegian University of Science and Technology Trondheim Norway

Department of Haemostasis Disorders and Internal Medicine Institute of Hematology and Transfusion Medicine Warsaw Poland

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital Bern Switzerland

Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic

Department of Hematology Jagiellonian University Medical College Krakow Poland

Department of Hematology Oncology and Pneumology Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany

Department of Hematology Oslo University Hospital Oslo Norway

Department of Hematology Shamir Medical Center Zerifin Israel

Department of Hematology St Olavs Hospital Trondheim University Hospital Trondheim Norway

Department of Nephrology Burgerspital Solothurn Switzerland

Department of Pediatric Hematology and Oncology University Medical Center Hamburg Eppendorf Hamburg Germany

Division of Hematology and Hemostasis Department of Medicine 1 Medical University of Vienna Vienna Austria

Division of Hematology and Oncology Versiti Blood Center of Wisconsin Medical College of Wisconsin Milwaukee Wisconsin USA

Institute of Hematology and Blood Transfusion Prague Czech Republic

Transfusion Medicine Institute Faculty of Health Sciences Ben Gurion University of the Negev Soroka University Medical Center Beer Sheva Israel

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031477
003      
CZ-PrNML
005      
20230127131159.0
007      
ta
008      
230119s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/rth2.12814 $2 doi
035    __
$a (PubMed)36284639
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tarasco, Erika $u Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland $u Department for BioMedical Research (DBMR) University of Bern Bern Switzerland $1 https://orcid.org/0000000243878476
245    10
$a Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease / $c E. Tarasco, AS. von Krogh, R. Hrdlickova, TR. Braschler, T. Iwaniec, PN. Knöbl, E. Hamada, O. Pikovsky, S. Farese, O. Gutwein, P. Kessler, NH. Schultz, C. von Auer, J. Windyga, K. Friedman, I. Hrachovinova, JN. George, M. Matsumoto, R. Schneppenheim, B. Lämmle, JA. Kremer Hovinga
520    9_
$a INTRODUCTION: Severe COVID-19 is associated with an important increase of von Willebrand factor and mild lowering of ADAMTS13 activity that may, in the presence of a strong inflammatory reaction, increase the risk of acute thrombotic thrombocytopenic purpura (TTP). Although acute episodes of immune-mediated TTP associated with COVID-19 or SARS-CoV-2 vaccination have been reported, data about clinical evolution of hereditary TTP (hTTP) during the pandemic are scarce. METHOD: We conducted a survey among adult patients of the International Hereditary TTP Registry about SARS-CoV-2 vaccination, COVID-19, and occurrence of acute hTTP episodes. RESULTS: Of 122 adult hTTP patients invited to participate, 86 (70.5%) responded. Sixty-five had been vaccinated (75.6%), of which 14 had received in addition a booster, resulting in 139 individual vaccine shots. Although vaccinations in patients on plasma prophylaxis were done within 1 week of the last plasma infusion, all 23 patients treated with plasma on demand were vaccinated without prior plasma infusions. One patient on uninterrupted weekly plasma infusions presented within 3 days from his second vaccination with neurological symptoms and computed tomography scan 9 days later showed subacute ischemic/hemorrhagic frontal lobe infarction. A second male patient developed acute myocarditis after his second dose of mRNA-1273 vaccine. Twelve (14%) patients had COVID-19, associated with an acute hTTP episode in three of them: one patient had a transient ischemic attack, one a stroke, and a pregnant woman was hospitalized to intensify plasma treatment. DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a von Krogh, Anne Sophie $u Department of Hematology St. Olavs Hospital, Trondheim University Hospital Trondheim Norway $u Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology Trondheim Norway
700    1_
$a Hrdlickova, Radomira $u Blood Center University Hospital Ostrava Ostrava Czech Republic
700    1_
$a Braschler, Thomas R $u Center for Clinical Hematology Luzerne Kantonsspital Lucerne Switzerland
700    1_
$a Iwaniec, Teresa $u Department of Hematology Jagiellonian University Medical College Krakow Poland
700    1_
$a Knöbl, Paul N $u Division of Hematology and Hemostasis, Department of Medicine I Medical University of Vienna Vienna Austria $1 https://orcid.org/0000000279097225
700    1_
$a Hamada, Eriko $u Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan $1 https://orcid.org/0000000309132475
700    1_
$a Pikovsky, Oleg $u Transfusion Medicine Institute, Faculty of Health Sciences, Ben-Gurion University of the Negev Soroka University Medical Center Beer-Sheva Israel
700    1_
$a Farese, Stefan $u Department of Nephrology Burgerspital Solothurn Switzerland
700    1_
$a Gutwein, Odit $u Department of Hematology Shamir Medical Center Zerifin Israel
700    1_
$a Kessler, Petr $u Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic
700    1_
$a Schultz, Nina H $u Department of Hematology Oslo University Hospital Oslo Norway
700    1_
$a von Auer, Charis $u Department of Hematology, Oncology, and Pneumology, Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany
700    1_
$a Windyga, Jerzy $u Department of Haemostasis Disorders and Internal Medicine Institute of Hematology and Transfusion Medicine Warsaw Poland
700    1_
$a Friedman, Kenneth $u Division of Hematology and Oncology, Versiti Blood Center of Wisconsin Medical College of Wisconsin Milwaukee Wisconsin USA
700    1_
$a Hrachovinova, Ingrid $u Institute of Hematology and Blood Transfusion Prague Czech Republic $1 https://orcid.org/0000000303002063
700    1_
$a George, James N $u Department of Biostatistics & Epidemiology College of Public Health, University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA
700    1_
$a Matsumoto, Masanori $u Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan $1 https://orcid.org/0000000272433126
700    1_
$a Schneppenheim, Reinhard $u Department of Pediatric Hematology and Oncology University Medical Center Hamburg-Eppendorf Hamburg Germany
700    1_
$a Lämmle, Bernhard $u Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland $u Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany $1 https://orcid.org/0000000345385154
700    1_
$a Kremer Hovinga, Johanna Anna $u Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland $u Department for BioMedical Research (DBMR) University of Bern Bern Switzerland $1 https://orcid.org/0000000213007135
773    0_
$w MED00196806 $t Research and practice in thrombosis and haemostasis $x 2475-0379 $g Roč. 6, č. 7 (2022), s. e12814
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36284639 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131151 $b ABA008
999    __
$a ok $b bmc $g 1889509 $s 1182810
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 6 $c 7 $d e12814 $e 20221021 $i 2475-0379 $m Research and practice in thrombosis and haemostasis $n Res Pract Thromb Haemost $x MED00196806
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace